Shield Therapeutics, a UK-listed company, directly sells a fully approved, patented, oral iron product, Accrufer, into the large and lucrative US market. This requires sales and marketing investments but captures all the profits enabling sustainable investment to gain higher returns. The two crucia
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Investing in iron
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-4.3%) | Mkt Cap: 11.5m
- Published:
04 Jul 2022 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
4
Shield Therapeutics, a UK-listed company, directly sells a fully approved, patented, oral iron product, Accrufer, into the large and lucrative US market. This requires sales and marketing investments but captures all the profits enabling sustainable investment to gain higher returns. The two crucia